期刊
BLOOD REVIEWS
卷 50, 期 -, 页码 -出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2021.100853
关键词
Hematopoietic stem cells; Hematopoietic stem cell transplantation; Umbilical cord blood; Gene therapy; Gene editing; ex vivo expansion
类别
Ex vivo expansion of hematopoietic stem cells is a promising strategy to overcome the barrier of low stem cell dose, broaden the availability of cord blood units for transplantation, and optimize the clinical application of gene therapy.
Hematopoietic stem cells (HSCs) have been used for therapeutic purposes for decades in the form of autologous and allogeneic transplantation and are currently emerging as an attractive target for gene therapy. A low stem cell dose is a major barrier to the application of HSC therapy in several situations, primarily umbilical cord blood transplantation and gene modification. Strategies that promote ex vivo expansion of the numbers of functional HSCs could overcome this barrier, hence have been the subject of intense and prolonged research. Several ex vivo expansion strategies have advanced to evaluation clinical trials, which are showing favorable outcomes along with convincing safety signals. Preclinical studies have recently confirmed beneficial incorporation of ex vivo expansion into HSC gene modification protocols. Collectively, ex vivo HSC expansion holds promise for significantly broadening the availability of cord blood units for transplantation, and for optimizing gene therapy protocols to enable their clinical application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据